NCT05946876View on ClinicalTrials.gov

A Phase 1 Study of XH-S003 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

August 24, 2023

Primary Completion Date

July 11, 2024

Study Completion Date

August 14, 2024

Conditions
Healthy
Interventions
DRUG

XH-S003 (A)

IP: XH-S003 IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

OTHER

Placebo (B)

Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

Trial Locations (1)

5000

CMAX Clinical Research, Adelaide

All Listed Sponsors
lead

S-INFINITY Pharmaceuticals Co., Ltd

INDUSTRY